Salisbury District Hospital is one of the first sites in the country to be involved in one of the biggest clinical trials in the UK to see whether aspirin can prevent cancers from coming back.
The ADD ASPIRIN trial will be run in around 100 centres within the country and will involve people who are having, or have had, treatment for early cancer.
Stef Scott, Head of Research at Salisbury District Hospital said: “This is an excellent achievement for Salisbury and another example of where reputation, local expertise, knowledge and a ‘can do’ attitude has been recognised, enabling us to be one of the first hospitals to offer patients an opportunity to take part in this high profile and important research project.”
“The best way to confirm if aspirin helps or not is to do a formal clinical trial and a number centres across the country will be taking part.”
“In Salisbury we will be looking to involve around 40 to 50 patients a year with their consent. Some will take aspirin and others will take a placebo (dummy) tablet. This this will be decided at random in order to make a fair comparison. They will be followed up for a number of years to collect all of the relevant information to see whether aspirin can delay or prevent their cancer from returning.”
Dr Scott added: “We expect the trial to last around 12 years and could give us a cheap and effective drug that will have a major impact on the way we treat cancers in the future. Patients who are interested in taking part in the ADD ASPIRIN trial should talk to their doctor, who will be able to consider whether they are suitable for the trial.”